Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FEEEM
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,119
Award facts
- Contract value 100% obligated
- $25,118.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $25,118.61 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on December 2, 2025, with an ultimate completion date of December 3, 2025, was executed without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is performing under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a broader $30.3 billion acquisition strategy that authorizes the delivery of firm fixed-price orders for comprehensive pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, vaccines, and medical consumables to support Department of Defense healthcare operations globally.
DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract (IDC) under the PPV-G GEN V initiative with a $499.999 billion ceiling value and completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods. The contractor's established performance across multiple delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of military healthcare facilities, with a product portfolio spanning oncology treatments, immunosuppressants, biologics, vaccines, emergency medications, and routine pharmaceuticals. No subcontractor relationships have been identified in the award documentation, and all federal contract funding has been provided by the DLA or its Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DU26FEEEM?
SPE2DU26FEEEM was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DU26FEEEM worth?
The government has obligated $25,119 on SPE2DU26FEEEM.
Is contract SPE2DU26FEEEM an order under another contract?
Yes. SPE2DU26FEEEM is a delivery order under SPE2DU25D9439, an indefinite delivery contract.
Was contract SPE2DU26FEEEM competed?
The extent of competition for SPE2DU26FEEEM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award